drugset / Trial / NCT03210532

Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia

NCT03210532

Phase 3 Completed 129 enrolled Daewon Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Multicenter, Randomized, Double-blinded, Double-dummy, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment with DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients with Hypertension and Dyslipidemia

Timeline

Start
2016-10-07
Primary completion
2017-09
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified Oral
Subject Rosuvastatin Small molecule Oral
Background Telmisartan Other / unclassified Oral